Omalizumab Treatment for Atopic Severe Persistant Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients.

Murat TurkSakine Nazik BahçecioğluNuri TutarFatma Sema OymakInci Gülmez İnsu Yılmaz

Published in: Turkish thoracic journal (2018)

Our results confirm that omalizumab significantly improves disease control and is a safe add-on therapy. In addition, in suitable patients with controlled disease over time, the step-down of other asthma medications will be appropriate.

Keyphrases

chronic obstructive pulmonary disease
end stage renal disease
lung function
ejection fraction
chronic kidney disease
prognostic factors
early onset
stem cells
patient reported outcomes
mesenchymal stem cells
bone marrow
air pollution
combination therapy